Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
NEW YORK, May 02, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Edge Therapeutics, Inc. ("Edge Therapeutics") (NASDAQ:EDGE) between December 29, 2017 and March 27, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra-d/edge-therapeutics-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Edge Therapeutics lead product candidate EG-1962 would likely fail a futility analysis in connection with the NEWTON 2 study; and (2) as a result of the foregoing, the Company's financial statements and Defendants' statements about Edge's business, operations, and prospects, were materially false and misleading at all relevant times.
If you suffered a loss in Edge Therapeutics you have until June 22, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
